Based on the best available evidence in humans, Ozempic does not appear to increase your chances of getting thyroid cancer. The concern comes from animal studies where rats developed thyroid tumors, but multiple large-scale human studies and a formal European Medicines Agency review have found no causal link between Ozempic and thyroid cancer in people.
That said, the FDA still requires a boxed warning on Ozempic’s label, and the drug is strictly off-limits for certain people with a family history of a rare thyroid cancer. Here’s what you need to know to put the risk in perspective.
Where the Concern Comes From
In rodent studies, semaglutide (the active ingredient in Ozempic) caused thyroid tumors in a dose-dependent way, meaning higher doses and longer treatment led to more tumors. These weren’t just any thyroid tumors. They were specifically C-cell tumors, which in humans correspond to a rare cancer called medullary thyroid carcinoma, or MTC.
This finding was significant enough that the FDA placed a boxed warning on Ozempic’s label, the most prominent safety warning a drug can carry. The warning states plainly: “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.” In other words, the FDA isn’t saying Ozempic causes thyroid cancer in people. It’s saying the question hasn’t been definitively settled.
Why Rat Results May Not Apply to Humans
Rats and humans have very different thyroid biology. Rodent thyroid C-cells are far more responsive to the type of receptor that Ozempic activates (the GLP-1 receptor), which is why tumors develop so readily in those studies. Human C-cells don’t respond the same way, and researchers at Mayo Clinic have pointed to detection bias rather than true causation as a more likely explanation for any signals seen in human data. When people start a new medication and get more medical attention, thyroid nodules that were already there are more likely to be found.
What Large Human Studies Show
A major Scandinavian cohort study published in The BMJ examined thyroid cancer rates in people taking GLP-1 receptor agonists like Ozempic compared to control groups. The study’s conclusion supported what the European Medicines Agency had already determined: the available evidence does not support a causal association between these drugs and thyroid cancer.
In October 2023, the EMA’s safety committee completed a comprehensive review that pulled together observational studies, clinical trial data, and post-marketing reports for all GLP-1 drugs on the market, including Ozempic, Wegovy, and others. Their conclusion was direct: no causal link to thyroid cancer, and no changes to product labeling were needed based on the data. Drugmakers are still required to monitor for any new signals and report them in ongoing safety updates.
How Rare Medullary Thyroid Cancer Actually Is
The specific cancer type tied to the rodent findings, medullary thyroid carcinoma, is extremely rare. Population data shows an incidence of roughly 0.14 cases per 100,000 people per year. To put that in context, between 1992 and 2006 in the United States, only 976 cases of MTC were diagnosed, compared to 36,583 cases of papillary thyroid cancer (the most common type) and 4,560 cases of follicular thyroid cancer. MTC accounts for a tiny fraction of all thyroid cancers, which are themselves uncommon.
This matters because even if Ozempic did slightly raise MTC risk (which current evidence doesn’t support), you’d be looking at a small increase in an already vanishingly small number.
Who Should Not Take Ozempic
Despite the reassuring human data, Ozempic carries a hard contraindication for two groups:
- People with a personal or family history of medullary thyroid carcinoma. If you or a close relative have been diagnosed with MTC, Ozempic is not an option.
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a genetic condition that dramatically increases MTC risk. It’s rare, but if you carry the diagnosis, GLP-1 drugs are ruled out.
If neither of these applies to you, the contraindication doesn’t affect your eligibility for the medication.
Monitoring While on Ozempic
You don’t need extra thyroid screening just because you’re taking Ozempic. Routine neck ultrasounds, calcitonin blood tests, or genetic testing for the mutations linked to hereditary MTC are not recommended unless you have specific symptoms or a relevant personal or family history. In fact, Ozempic’s own prescribing information notes that routine calcitonin monitoring could lead to unnecessary procedures because of the test’s low specificity and the high background rate of benign thyroid findings in the general population.
What you should be aware of are the symptoms that would warrant attention regardless of what medication you’re taking: a noticeable lump or mass in the neck, difficulty swallowing, trouble breathing, or persistent hoarseness that doesn’t resolve. These are general red flags for thyroid problems, not specific side effects of Ozempic.
Putting the Risk in Perspective
The boxed warning on Ozempic understandably alarms people, but boxed warnings reflect a precautionary standard, not a confirmed danger. The FDA requires the warning because the rodent data was concerning enough to flag, and human studies haven’t been long enough or large enough to completely rule out a tiny risk with absolute certainty. That’s a very different thing from evidence that the drug causes cancer.
Every major regulatory body that has reviewed the full scope of evidence, including the EMA’s dedicated 2023 investigation, has reached the same conclusion: no causal link between GLP-1 receptor agonists and thyroid cancer in humans. For the vast majority of people considering or currently using Ozempic, thyroid cancer risk does not appear to be meaningfully changed by the medication.